- Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial product
- Aditxt recently announced it had authorized a new channel partner – Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab –to offer AditxtScore(TM)
- This announcement comes amid reports warning of a fall and winter COVID-19 wave occasioned by waning immunity or a possible “nasty new variant”
- Already, the U.S. is undergoing a sixth wave even before the start of the summer
During the one week to May 18, the U.S. averaged roughly 100,000 COVID-19 cases each day, representing an increase of more than 3x from the lowest figure reported in March, yet the numbers did not include at-home test results, according to a Washington Post article. The piece quotes experts’ assumptions that the infections in their communities are five to ten times the official counts (https://ibn.fm/QgkXo).
Despite the disparity in the reported figures, the sheer number of infections is still a cause for concern, with White House health officials urging Americans to stay up-to-date with vaccines and booster shots, get tested, and wear masks. And as the country ushers in the summer season, experts are quick to sound alarm bells, warning that this summer’s surge in COVID-19 cases could be worse than last year’s because the May 2022 cases were considerably higher than they were a year earlier.
“Federal officials have also warned of a possible fall and winter wave that could result in 100 million coronavirus infections driven by omicron subvariants that have shown a remarkable ability to escape immunity,” the article reads. Christopher Murray, Director of the Institute for Health Metrics and Evaluation, told the Washington Post that the anticipated spike in COVID-19 cases this fall and winter could be the result of a substantial dip in immunity or “some nasty new variant.” Already, the U.S. is undergoing a sixth wave even before the start of the summer (https://ibn.fm/wkCPJ).
The immunity’s role in keeping SARS-CoV-2 – the virus that causes the COVID-19 disease – at bay has been recognized and appreciated by many experts and companies, one of which is Aditxt (NASDAQ: ADTX). Aditxt provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system.
Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them. This product can be used routinely to establish changes in immune response over time (immunity trends) and provide information crucial to understanding the virus, especially amid reports of a possible fall and winter wave. The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies.
Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are a result of vaccination or an immune response to a virus; whether the immune response is likely to protect against future infection; and the possible ways to minimize the risk of a future infection.
The benefits of AditxtScore(TM) will now be felt by an even larger population following a recent announcement that Premier Medical Laboratory Services (“PMLS”), a leading advanced medical diagnostics lab, has added this product to its list of testing services. Under the terms of this arrangement, PMLS is an authorized channel partner that will offer AditxtScore(TM) (https://ibn.fm/MvMdX).
“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” commented Kevin Murdock, CEO of PMLS. “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.”
PMLS joins a list of channel partners that includes the Great Lakes Medical Laboratory, Inc., The Health Watchers, Physicians Stat Lab, Sphere Dx Laboratory, and HealthBar. These partners collect and ship samples to the AditxtScore(TM) Center, Aditxt’s high complexity CLIA-certified, CAP-accredited lab, where the specimens are prepped and profiled by a team of lab scientists trained at prestigious institutions. According to the company, the results are usually readied within 48 hours of specimens’ receipt (https://ibn.fm/F3BYU).
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment